HISOAR(SZ:002099) Sou Hu Cai Jing·2025-10-19 20:35Core Viewpoint - The company is actively investing in innovative drug projects and exploring collaboration opportunities to expand its business in response to the growing market for innovative pharmaceuticals [2]. Group 1: Company Performance - As of October 17, 2025, the company's stock price closed at 5.6 yuan, reflecting a decrease of 1.93% with a turnover rate of 0.53% and a trading volume of 85,900 shares, resulting in a transaction amount of 48.68 million yuan [1]. Group 2: Investment and Innovation Strategy - The company has invested in several innovative drug and treatment projects through its subsidiary fund, focusing on areas such as HPV infection and liver cancer therapeutic vaccines, TCR-T cell therapy, and recombinant drugs, with some projects already in clinical stages and receiving government funding and investments from Hong Kong-listed companies [2]. - The company is closely monitoring domestic and international pharmaceutical industry trends and is leveraging its accumulated customer base, production capabilities, and technological advantages to seek opportunities for collaboration on innovative drug projects [2]. Group 3: Market Activity - On October 17, the net outflow of funds from major investors was 351,800 yuan, while speculative funds saw a net inflow of 1,111,500 yuan, and retail investors experienced a net outflow of 759,700 yuan [2].